Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
TRAP
MCID: TRD008
MIFTS: 33

Triiodothyronine Receptor Auxiliary Protein (TRAP)

Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Triiodothyronine Receptor Auxiliary Protein

About this section

MalaCards integrated aliases for Triiodothyronine Receptor Auxiliary Protein:

Name: Triiodothyronine Receptor Auxiliary Protein 57
Trap 57

External Ids:

OMIM® 57 190445
Sources

Summaries for Triiodothyronine Receptor Auxiliary Protein

About this section
MalaCards based summary : Triiodothyronine Receptor Auxiliary Protein, also known as trap, is related to spondyloenchondrodysplasia with immune dysregulation and neural tube defects. An important gene associated with Triiodothyronine Receptor Auxiliary Protein is TRAP (Triiodothyronine Receptor Auxiliary Protein). The drugs Heparin and Dalteparin have been mentioned in the context of this disorder. Affiliated tissues include bone, neutrophil and endothelial.

More information from OMIM: 190445
Sources

Related Diseases for Triiodothyronine Receptor Auxiliary Protein

About this section

Diseases related to Triiodothyronine Receptor Auxiliary Protein via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 775)
# Related Disease Score Top Affiliating Genes
1 spondyloenchondrodysplasia with immune dysregulation 11.1
2 neural tube defects 11.0
3 hidradenitis suppurativa 10.9
4 immune system disease 10.9
5 malaria 10.4
6 bone resorption disease 10.2
7 vaccinia 10.2
8 vasculitis 10.2
9 macular degeneration, age-related, 1 10.2
10 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
11 hair whorl 10.2
12 west nile virus 10.2
13 lupus erythematosus 10.2
14 lung cancer 10.1
15 microvascular complications of diabetes 5 10.1
16 ischemia 10.1
17 encephalitis 10.1
18 cytokine deficiency 10.1
19 rapidly involuting congenital hemangioma 10.1
20 proteinuria, chronic benign 10.1
21 chikungunya 10.1
22 rabies 10.1
23 chronic granulomatous disease 10.1
24 anca-associated vasculitis 10.1
25 systemic lupus erythematosus 10.1
26 volvulus of midgut 10.1
27 cystic fibrosis 10.1
28 middle east respiratory syndrome 10.1
29 leukemia 10.1
30 hairy cell leukemia 10.1
31 macular retinal edema 10.1
32 polyhydramnios 10.1
33 pancreatitis 10.1
34 congestive heart failure 10.1
35 periodontitis 10.1
36 peritonitis 10.1
37 arthritis 10.1
38 lung disease 10.1
39 yellow fever 10.1
40 47,xyy 10.1
41 meester-loeys syndrome 10.0
42 helix syndrome 10.0
43 kuhnt-junius degeneration 10.0
44 acute pancreatitis 10.0
45 haemophilus influenzae 10.0
46 atrial standstill 1 10.0
47 breast cancer 10.0
48 osteogenic sarcoma 10.0
49 yemenite deaf-blind hypopigmentation syndrome 10.0
50 thrombosis 10.0

Graphical network of the top 20 diseases related to Triiodothyronine Receptor Auxiliary Protein:



Diseases related to Triiodothyronine Receptor Auxiliary Protein
Sources

Symptoms & Phenotypes for Triiodothyronine Receptor Auxiliary Protein

About this section

Clinical features from OMIM®:

190445 (Updated 05-Mar-2021)

Sources

Drugs & Therapeutics for Triiodothyronine Receptor Auxiliary Protein

About this section

Drugs for Triiodothyronine Receptor Auxiliary Protein (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 191)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
2
Dalteparin Approved Phase 4 9005-49-6
3
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
4 Certoparin Approved, Investigational Phase 4
5
Verteporfin Approved, Investigational Phase 4 129497-78-5
6
Thrombin Approved, Investigational Phase 4
7
Vorapaxar Approved Phase 4 618385-01-6
8
Rilonacept Approved, Investigational Phase 4 501081-76-1 104924
9
Ranibizumab Approved Phase 4 347396-82-1 459903
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11 calcium heparin Phase 4
12 Fibrinolytic Agents Phase 4
13 Heparin, Low-Molecular-Weight Phase 4
14
Terephthalic acid Phase 4 100-21-0 7489
15 Anti-Inflammatory Agents Phase 4
16 Vaccines Phase 4
17 Pharmaceutical Solutions Phase 4
18 Anesthetics Phase 4
19
tannic acid Approved Phase 3 1401-55-4
20
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
21
Colchicine Approved Phase 3 64-86-8 6167 2833
22 Dialysis Solutions Phase 3
23 Protamines Phase 3
24 Photosensitizing Agents Phase 3
25 Angiogenesis Inhibitors Phase 3
26 Immunoglobulins Phase 3
27 Immunoglobulins, Intravenous Phase 3
28 Antibodies Phase 3
29
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
30
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
31
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
32
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
33
Trastuzumab Approved, Investigational Phase 1, Phase 2 180288-69-1 9903
34
Pertuzumab Approved Phase 1, Phase 2 380610-27-5, 145040-37-5 2540
35
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
36
Olaparib Approved Phase 2 763113-22-0 23725625
37
Durvalumab Approved, Investigational Phase 2 1428935-60-7
38
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
39
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
40
Metronidazole Approved Phase 1, Phase 2 443-48-1 4173
41
Dantrolene Approved, Investigational Phase 1, Phase 2 7261-97-4 2952 6914273
42
Pioglitazone Approved, Investigational Phase 1, Phase 2 111025-46-8 4829
43
Clemastine Approved, Investigational Phase 1, Phase 2 15686-51-8 26987
44
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6, 75614-87-8 774
45
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
46
Atezolizumab Approved, Investigational Phase 1, Phase 2 1380723-44-3
47
Fluorouracil Approved Phase 2 51-21-8 3385
48
leucovorin Approved Phase 2 58-05-9 6006
49
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
50
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436

Interventional clinical trials:

(show top 50) (show all 192)
# Name Status NCT ID Phase Drugs
1 Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
2 MGuard vs bAre-metal Stents Plus Manual Thrombectomy in Real World STEMI Patients: a Prospective Multicenter Randomized Trial Unknown status NCT01124942 Phase 4
3 Reassessment Study of The Effect of N-Acetylcystein on Quality of Life and Air Trapping During Rest and After Exercise Unknown status NCT00476736 Phase 4 Effect on small airways (N-Acetylcystein)
4 Vorapaxar in the Human Endotoxemia Model A Randomized, Double-Blind, Crossover Study Completed NCT02875028 Phase 4 Vorapaxar;Placebo
5 Efficacy of Intravitreal Aflibercept Monotherapy for Submacular Hemorrhage Secondary to Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial Completed NCT03169660 Phase 4 Vascular endothelial growth factor trap-eye
6 An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4 aflibercept
7 An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration Completed NCT01722045 Phase 4 Intravitreal Aflibercept Injection (IAI)
8 Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy Completed NCT02072408 Phase 4 aflibercept
9 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
10 Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD) Completed NCT01663103 Phase 4 Rilonacept;Placebo
11 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples Recruiting NCT01824537 Phase 4
12 Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence: an Open-label Randomized Controlled Trial: TRAPIST - TRAP Intervention STudy Recruiting NCT02621645 Phase 4
13 Estimation of MMP-8 Levels in GCF and Serum and Its Correlation With Wound Healing and Clinical Outcomes After Coronally Advanced Flap and Subepithelial Connective Tissue Graft for Root Coverage in Recession Defects: A CLINICO-BIOCHEMICAL STUDY Suspended NCT02863744 Phase 4
14 A Randomized Controlled Trial of Integrated Traditional Chinese and Western Medicine in the Treatment of Severe Community Acquired Pneumonia Unknown status NCT03185923 Phase 3 TCM plus conventional drug;TCM placebo plus conventional drug
15 Influence of Preoperative Hemodialysis or Intraoperative Modified Ultrafiltration on Postoperative Outcome for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery: Randomized, Controlled, Multicenter Clinical Trial Unknown status NCT00720967 Phase 3
16 A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap Eye in Subjects With Diabetic Macular Edema Completed NCT01783886 Phase 3
17 A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap-Eye in Subjects With Diabetic Macular Edema Completed NCT01331681 Phase 3
18 A Randomized, Double-masked, Photodynamic Therapy-controlled Phase-3 Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Chinese Subjects With Neovascular Age-Related Macular Degeneration Completed NCT01482910 Phase 3 Visudyne
19 An Open-label Phase III Study Evaluating the Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap-Eye in Japanese Subjects With Diabetic Macular Edema Completed NCT01512966 Phase 3
20 A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema Completed NCT01363440 Phase 3 Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
21 Trial to Reduce Alloimmunization to Platelets (TRAP) Completed NCT00000589 Phase 3
22 A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT00943072 Phase 3 Sham
23 A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Completed NCT01012973 Phase 3
24 A Phase-3, Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects With Choroidal Neovascularization Secondary to Pathologic Myopia Completed NCT01249664 Phase 3
25 A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (AMD) Completed NCT00637377 Phase 3 Ranibizumab
26 A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT01521559 Phase 3 Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
27 An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration Completed NCT00964795 Phase 3 Intravitreal Aflibercept Injection 2mg
28 A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration Completed NCT00509795 Phase 3
29 A Randomized, Double-blind, Placebo Controlled Study of Canakinumab in Patients With Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), With Subsequent Randomized Withdrawal/Dosing Frequency Reduction and Open-label Long-term Treatment Epochs Completed NCT02059291 Phase 3 Canakinumab;Placebo
30 Indwelling Pleural Catheter for Trapped Lung: a Pilot Study for Power Calculation of a Randomized Controlled Trial Comparing Pleurocath® Versus PleurX®) Completed NCT03550027 Phase 3
31 A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) Completed NCT02334748 Phase 3 canakinumab
32 An Extension Study of CACZ885N2301 (NCT02059291), Multi-center, Open Label Study of Canakinumab in Japanese Patients With Periodic Fever Syndromes (Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyper Immunoglobulin D Syndrome ((Also Known as Mevalonate Kinase Deficiency) (HIDS/MKD), or Colchicine Resistant/Intolerant Familial Mediterranean Fever (crFMF)) Completed NCT02911857 Phase 3
33 A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration Completed NCT00320788 Phase 2
34 A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1 Completed NCT01739036 Phase 1, Phase 2
35 A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP Completed NCT01142765 Phase 1, Phase 2
36 A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01B + ChAd63 and MVA Encoding ME-TRAP and Also RTS,S/AS01B Alone. Completed NCT01883609 Phase 1, Phase 2
37 Efficacy Study of ChAd63MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection. Completed NCT01666925 Phase 2
38 Efficacy Study of ChAd63-MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection Completed NCT01658696 Phase 2
39 A Phase 1/2b Double Blind Randomised Controlled Trial of the Efficacy, Safety and Immunogenicity of Heterologous Prime-boost Immunisation With the Candidate Malaria Vaccines ChAd63 ME-TRAP and MVA ME-TRAP in 5-17 Month Old Burkinabe Infants and Children Completed NCT01635647 Phase 1, Phase 2
40 A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-Boost Malaria Vaccine Candidates: ChAd63 and MVA Encoding ME-TRAP and the Same Viral Vectors Encoding CS Completed NCT01623557 Phase 1, Phase 2
41 Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With AdCh63 ME-TRAP and MVA ME-TRAP Completed NCT00890760 Phase 1, Phase 2
42 An Open-label, Multicenter, Efficacy and Safety Study of 4-month Canakinumab Treatment With 6-month Follow-up in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS). Completed NCT01242813 Phase 2 ACZ885
43 OPTIMOX-aflibercept as First-line Therapy in 49 Patients With Unresectable Metastatic Colorectal Cancer. A GERCOR Feasibility Single-arm Phase II Study. Completed NCT01802684 Phase 2
44 Phase I/II and Pharmacokinetic Study of Docetaxel Plus VEGF Trap (AVE0005, NSC# 724770) in Patients With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Completed NCT00436501 Phase 1, Phase 2 docetaxel
45 A Phase I/IIa Sporozoite Challenge Study to Assess the Safety, Immunogenicity and Protective Efficacy of Intravenous Boosting With Malaria Vaccine Candidates ChAd63 and MVA Encoding ME-TRAP Completed NCT03707353 Phase 1, Phase 2
46 Phase 2 Study of IL-1 Trap (Rilonacept) for Treatment of Familial Mediterranean Fever (FMF) Completed NCT00582907 Phase 2 Rilonacept;Placebo
47 A Phase 2 Study Evaluating the Efficacy of VEGF Trap in Patients With Recurrent Inoperable Stage III or Stage IV Melanoma Completed NCT00450255 Phase 2
48 A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma Completed NCT00357760 Phase 2
49 A Multicenter, Randomized, Double-blind, Parallel-arm, Two-stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients With Platinum-resistant and topotecan-and/or Liposomal Doxorubicin-resistant Advanced Ovarian Cancer Completed NCT00327171 Phase 2 Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
50 Continuation of a Pilot Open-Label Study of IL 1 Trap in Adult Subjects With Autoinflammatory Diseases: A Therapeutic Approach to Study Pathogenesis Completed NCT00094900 Phase 2 IL-1 Trap

Search NIH Clinical Center for Triiodothyronine Receptor Auxiliary Protein

Sources

Genetic Tests for Triiodothyronine Receptor Auxiliary Protein

About this section
Sources

Anatomical Context for Triiodothyronine Receptor Auxiliary Protein

About this section

MalaCards organs/tissues related to Triiodothyronine Receptor Auxiliary Protein:

40
Bone, Neutrophil, Endothelial, Bone Marrow, Liver, Lung, Eye
Sources

Publications for Triiodothyronine Receptor Auxiliary Protein

About this section

Articles related to Triiodothyronine Receptor Auxiliary Protein:

(show top 50) (show all 30001)
# Title Authors PMID Year
1
3,5,3'-triiodothyronine receptor auxiliary protein (TRAP) enhances receptor binding by interactions within the thyroid hormone response element. 61 57
1708100 1991
2
Characterization of edaphic fauna in different monocultures in Savanna of Piauí. 61
32876170 2021
3
The study of gp130/the inflammatory factors regulating osteoclast differentiation in rheumatoid arthritis. 61
33604457 2021
4
Nanographene oxide modified phenyl methanethiol nanomagnetic composite for rapid separation of aluminum in wastewaters, foods, and vegetable samples by microwave dispersive magnetic micro solid-phase extraction. 61
33482488 2021
5
Structural changes induced by direct current magnetic field improve water holding capacity of pork myofibrillar protein gels. 61
33601660 2021
6
Acute ischemic stroke induces magnetic resonance susceptibility signs dominated by endothelial nitric oxide synthase activation. 61
33128486 2021
7
Fabrication of an electrochemical biodevice for ractopamine detection under a strategy of a double recognition of the aptamer/molecular imprinting polymer. 61
33340819 2021
8
Multiple stressors and social-ecological traps in Pampean streams (Argentina): A conceptual model. 61
33097269 2021
9
Schistosoma japonicum cystatin suppresses osteoclastogenesis via manipulating the NF‑κB signaling pathway. 61
33576450 2021
10
Speciation of germanium in environmental water reference materials by hydride generation and cryotrapping in combination with ICP-MS/MS. 61
33592806 2021
11
Influence of Plasma Ultraviolet/Vacuum Ultraviolet Irradiation Damage on Silicon Metal-Oxide-Semiconductor Capacitor During Etching. 61
33500031 2021
12
Residential proximity to major roadways and cognitive function among Chinese adults 65 years and older. 61
33097247 2021
13
TRAPγ-CDG shows asymmetric glycosylation and an effect on processing of proteins required in higher organisms. 61
32332102 2021
14
Effect of Sacrificial AlN (Aluminum Nitride) Layer on the Deep Surface States of 4H-SiC. 61
33404466 2021
15
Minimizing ion competition boosts volatile metabolome coverage by secondary electrospray ionization orbitrap mass spectrometry. 61
33583550 2021
16
A Subpopulation of Prefrontal Cortical Neurons Is Required for Social Memory. 61
33190846 2021
17
Platelet dysfunction in a large-animal model of endotoxic shock; effects of inhaled nitric oxide and low-dose steroid. 61
33400993 2021
18
Electrical stimulation of hindlimb skeletal muscle has beneficial effects on sublesional bone in a rat model of spinal cord injury. 61
33348128 2021
19
Proximity to traffic and exposure to polycyclic aromatic hydrocarbons in relation to Attention Deficit Hyperactivity Disorder and conduct disorder in U.S. children. 61
33429141 2021
20
QingYan formula extracts protect against postmenopausal osteoporosis in ovariectomized rat model via active ER-dependent MEK/ERK and PI3K/Akt signal pathways. 61
33264660 2021
21
Modulation of the liver immune microenvironment by the adeno-associated virus serotype 8 gene therapy vector. 61
33376758 2021
22
Hole transport free flexible perovskite solar cells with cost-effective carbon electrodes. 61
33260165 2021
23
An assessment of gully pot sediment scour behaviour under current and potential future rainfall conditions. 61
33450433 2021
24
Multinucleated giant cells within the in vivo implantation bed of a collagen-based biomaterial determine its degradation pattern. 61
32514904 2021
25
Development and validation of a QTrap method for sensitive quantification of sphingosine 1-phosphate. 61
33063871 2021
26
Adaptive Granularity Learning Distributed Particle Swarm Optimization for Large-Scale Optimization. 61
32224474 2021
27
Applications of direct analysis in real time mass spectrometry in food analysis: A review. 61
33277776 2021
28
M2-like macrophage infiltration and transforming growth factor-β secretion during socket healing process in mice. 61
33482540 2021
29
Exosomes from TNF-α-treated human gingiva-derived MSCs enhance M2 macrophage polarization and inhibit periodontal bone loss. 61
33359765 2021
30
Proactive Air Management in CT Power Injections: A Comprehensive Approach to Reducing Air Embolization. 61
32746030 2021
31
Leakage Current Analysis Method for Metal Insulator Semiconductor Capacitors Through Low-Frequency Noise Measurement. 61
33404477 2021
32
Visible light photocatalytic degradation of polypropylene microplastics in a continuous water flow system. 61
33131945 2021
33
Mesoscopic engineering materials for visual detection and selective removal of copper ions from drinking and waste water sources. 61
33168312 2021
34
Obstructive lung diseases and allergic bronchopulmonary aspergillosis. 61
33394749 2021
35
Discrimination of isomeric monosaccharide derivatives using collision-induced fingerprinting coupled to ion mobility mass spectrometry. 61
33379106 2021
36
A straightforward gel-free proteomics pipeline assisted by liquid isoelectric focusing (OFFGEL) and mass spectrometry analysis to study bovine meat proteome. 61
32600057 2021
37
Current understanding and challenges for aquatic primary producers in a world with rising micro- and nano-plastic levels. 61
33321322 2021
38
From source to sink: Review and prospects of microplastics in wetland ecosystems. 61
33223161 2021
39
Activation of peroxymonosulfate by calcined electroplating sludge for ofloxacin degradation. 61
33257045 2021
40
The Satisfaction with Life Scale: Philosophical Foundation and Practical Limitations. 61
33386535 2021
41
Targeting unique biological signals on the fly to improve MS/MS coverage and identification efficiency in metabolomics. 61
33551064 2021
42
Nuclear-Encoded lncRNA MALAT1 Epigenetically Controls Metabolic Reprogramming in HCC Cells through the Mitophagy Pathway. 61
33425485 2021
43
N-nitrosoethylenethiourea formation at environmentally-relevant concentrations of ethylenethiourea in a pooled groundwater sample. 61
33243502 2021
44
Efficacy of aggregation nano gel pheromone traps on the catchability of Rhynchophorus ferrugineus (Olivier) in Egypt. 61
33027341 2021
45
Effect of Reducing Ambient Traffic-Related Air Pollution on Blood Pressure: A Randomized Crossover Trial. 61
33486990 2021
46
The effect of lipoxin A4 on E. coli LPS-induced osteoclastogenesis. 61
32506323 2021
47
Activated Neutrophils Propagate Fetal Membrane Inflammation and Weakening through ERK and Neutrophil Extracellular Trap-Induced TLR-9 Signaling. 61
33472905 2021
48
Quantification of mRNA ribosomal engagement in human neurons using parallel translating ribosome affinity purification (TRAP) and RNA sequencing. 61
33364619 2021
49
Rapid detection of trace formaldehyde in food based on surface-enhanced Raman scattering coupled with assembled purge trap. 61
32871357 2021
50
Municipal wastewater as an ecological trap: Effects on fish communities across seasons. 61
33187712 2021
Sources

Variations for Triiodothyronine Receptor Auxiliary Protein

About this section
Sources

Expression for Triiodothyronine Receptor Auxiliary Protein

About this section
Search GEO for disease gene expression data for Triiodothyronine Receptor Auxiliary Protein.
Sources

Pathways for Triiodothyronine Receptor Auxiliary Protein

About this section
Sources

GO Terms for Triiodothyronine Receptor Auxiliary Protein

About this section
Sources

Sources for Triiodothyronine Receptor Auxiliary Protein

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....